Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026

Phathom Pharmaceuticals (PHAT) will report third quarter 2026 financial results and provide a business update on October 29, 2026.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Phathom Pharmaceuticals (PHAT) will report third quarter 2026 financial results and provide a business update on October 29, 2026.

Management will host a live webcast at 8:00 am EDT, accessible through the Events & Presentations section of the company’s website. A recording will remain available for 90 days after the call.

Key Terms

pcab, gerd

2 terms

pcab medical

"a first-in-class potassium-competitive acid blocker (PCAB)"

PCAB is the Philippine Contractors Accreditation Board, the government body that issues licenses and size classifications to construction contractors—think of it like a combined business license and capacity rating for builders. Investors pay attention because a contractor’s PCAB license and grade determine which public and private projects it can legally bid on and the maximum project size it may undertake; changes in status can directly affect a firm’s revenue opportunities and regulatory risk profile.

gerd medical

"Non-Erosive GERD in adults"

Gastroesophageal reflux disease (GERD) is a chronic condition where stomach acid or contents flow back into the food pipe, causing heartburn, throat irritation, and sometimes damage to the lining. For investors, GERD matters because it drives demand for medications, medical devices, and procedures, influences healthcare spending and insurer costs, and can affect the valuation and revenue prospects of companies developing treatments or diagnostic tools — similar to how recurring maintenance needs shape demand in other industries.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/19/2026 - 08:00 AM EDT

Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDT

FLORHAM PARK, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, October 29, 2026, to report its third quarter 2026 financial results and provide a business update.

A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the call.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA^® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA^® TRIPLE PAK^® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA^® DUAL PAK^® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.